Annual Report 2022

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2022 88 The United Laboratories International Holdings Limited Annual Report 2022 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information HKFRS 8 Operating Segments requires operating segments to be identified on the basis of internal reports about components of the Group that are regularly reviewed by the chief operating decision maker (“CODM”) (i.e. executive directors of the Company) for the purpose of allocating resources to segments and assessing their performance. The three revenue streams are the operating and reportable segments of the Group on which the Group reports its primary segment information. (a) Segment revenue and results Year ended 31 December 2022 Intermediate Bulk Finished Segment products medicine products total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 REVENUE External sales 1,599,205 5,174,726 4,560,331 11,334,262 – 11,334,262 Inter-segment sales 2,718,504 870,178 – 3,588,682 (3,588,682) – Segment revenue 4,317,709 6,044,904 4,560,331 14,922,944 (3,588,682) 11,334,262 RESULT Segment profit 918,762 385,722 796,191 2,100,675 Share of results of an associate (189) Unallocated other income 104,125 Unallocated corporate expenses (97,343) Unallocated other gains and losses, net (22,378) Impairment losses reversed under expected credit loss model, net 3,471 Finance costs (81,595) Profit before taxation 2,006,766